Measurement of the amount of time that CPAP is used on average per night over the outcome time frame
| Group | Value | 95% CI |
|---|---|---|
| Sleep Apnea Self-Management Program | 2.1 | ± 1.5 |
| Individualized Pressure Adjustment | 2.2 | ± 1.6 |
Last reviewed · How we verify
Self-Management of Continuous Positive Airway Pressure Settings
NA trial testing Sleep Apnea Self-Management Program in Obstructive Sleep Apnea in 270 participants. Completed in 30 April 2023.
| Lead sponsor | VA Office of Research and Development |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 270 |
| Start date | 1 October 2018 |
| Primary completion | 31 March 2023 |
| Estimated completion | 30 April 2023 |
| Sites | 1 location across United States |
VA Office of Research and Development — full company profile →
Adults 18 to 70, any sex, with Obstructive Sleep Apnea. Patients with the condition only — healthy volunteers not accepted.
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Measurement of the amount of time that CPAP is used on average per night over the outcome time frame
| Group | Value | 95% CI |
|---|---|---|
| Sleep Apnea Self-Management Program | 2.1 | ± 1.5 |
| Individualized Pressure Adjustment | 2.2 | ± 1.6 |
Obstructive sleep apnea (OSA) is a major chronic condition affecting the quality of life of millions of Americans. Per the Institute of Medicine new treatment adherence strategies are needed to help improve the quality of care, reduce social and economic costs, and help those with chronic conditions, including OSA, live healthier and more productive lives through better management of their conditions. Adherence with continuous positive airway pressure (PAP) therapy is disappointingly low, and new methods to increase both the use and efficacy of therapy are needed. Historically, patients have not been formally instructed to adjust their pressure settings on their PAP devices; practically, however, allowing patients to adjust their pressure settings fosters engagement, self-confidence, and control with therapy.
1 peer-reviewed publication reference this trial (live from Europe PMC):
Verify or expand the search:
Currently open trials in the same condition.
Trials by the same sponsor.
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03536572.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing